These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28257903)

  • 1. Does a triple combination have better activity than double combinations against multiresistant fungi? Experimental in vitro evaluation.
    Martin-Vicente A; Guarro J; Capilla J
    Int J Antimicrob Agents; 2017 Apr; 49(4):422-426. PubMed ID: 28257903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do antibacterial and antifungal combinations have better activity against clinically relevant fusarium species? in vitro synergism.
    Venturini TP; Al-Hatmi AMS; Rossato L; Azevedo MI; Keller JT; Weiblen C; Santurio JM; Alves SH
    Int J Antimicrob Agents; 2018 May; 51(5):784-788. PubMed ID: 29127050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.
    Cuenca-Estrella M; Gomez-Lopez A; Buitrago MJ; Mellado E; Garcia-Effron G; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2248-50. PubMed ID: 16723597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of a wide panel of antifungal drugs against various Scopulariopsis and Microascus species.
    Skóra M; Bulanda M; Jagielski T
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5827-9. PubMed ID: 26100698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
    Drogari-Apiranthitou M; Mantopoulou FD; Skiada A; Kanioura L; Grammatikou M; Vrioni G; Mitroussia-Ziouva A; Tsakris A; Petrikkos G
    J Antimicrob Chemother; 2012 Aug; 67(8):1937-40. PubMed ID: 22535624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the expanding spectrum of sertraline against uncommon fungal pathogens.
    Villanueva-Lozano H; González GM; Espinosa-Mora JE; Bodden-Mendoza BA; Andrade A; Martínez-Reséndez MF; Treviño-Rangel RJ
    J Infect Chemother; 2020 Mar; 26(3):309-311. PubMed ID: 31678053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii.
    Li H; Lu Q; Wan Z; Zhang J
    Int J Antimicrob Agents; 2010 Jun; 35(6):550-2. PubMed ID: 20202797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
    Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp.
    Shalit I; Shadkchan Y; Mircus G; Osherov N
    Med Mycol; 2009; 47(5):457-62. PubMed ID: 18720217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.
    Meletiadis J; Stergiopoulou T; O'Shaughnessy EM; Peter J; Walsh TJ
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2053-64. PubMed ID: 17387150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis.
    Schemuth H; Dittmer S; Lackner M; Sedlacek L; Hamprecht A; Steinmann E; Buer J; Rath PM; Steinmann J
    Mycoses; 2013 May; 56(3):297-303. PubMed ID: 23170818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro resistance of clinical Fusarium species to amphotericin B and voriconazole using the EUCAST antifungal susceptibility method.
    Taj-Aldeen SJ; Salah H; Al-Hatmi AM; Hamed M; Theelen B; van Diepeningen AD; Boekhout T; Lass-Flörl C
    Diagn Microbiol Infect Dis; 2016 Aug; 85(4):438-43. PubMed ID: 27312690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp.
    Demchok JP; Meletiadis J; Roilides E; Walsh TJ
    Mycoses; 2010 May; 53(3):239-45. PubMed ID: 19389068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of Amphotericin B Formulations and Voriconazole, Alone or in Combination, against Biofilms of
    Vikelouda K; Simitsopoulou M; Skoura L; Antachopoulos C; Roilides E
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0063821. PubMed ID: 34370583
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity of MSI-78, h-Lf1-11 and cecropin B antimicrobial peptides alone and in combination with voriconazole and amphotericin B against clinical isolates of Fusarium solani.
    Denardi LB; Weiblen C; Ianiski LB; Stibbe PC; Santurio JM
    J Mycol Med; 2021 Jun; 31(2):101119. PubMed ID: 33626413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium.
    Badali H; Khodavaisy S; Fakhim H; de Hoog GS; Meis JF; Chowdhary A
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7818-22. PubMed ID: 26369976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postantifungal effect of the combination of caspofungin with voriconazole and amphotericin B against clinical Candida krusei isolates.
    Oz Y; Kiremitci A; Dag I; Metintas S; Kiraz N
    Med Mycol; 2013 Jan; 51(1):60-5. PubMed ID: 22746405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
    Philip A; Odabasi Z; Rodriguez J; Paetznick VL; Chen E; Rex JH; Ostrosky-Zeichner L
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3572-4. PubMed ID: 16048988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans.
    Wiederhold NP; Law D; Birch M
    J Antimicrob Chemother; 2017 Jul; 72(7):1977-1980. PubMed ID: 28333310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species.
    O'Shaughnessy EM; Meletiadis J; Stergiopoulou T; Demchok JP; Walsh TJ
    J Antimicrob Chemother; 2006 Dec; 58(6):1168-76. PubMed ID: 17071635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.